ProSomnus SPAC Presentation Deck

ProSomnus is NOT Like Other OATS ProSomnus device technology addresses the limitations of legacy OATS and results in superior performance DATA SUPPORTS PROSOMNUS HAS A SUPERIOR PRODUCT¹ NORTH AMERICAN REVENUE GROWTH VS. OAT COMPETITOR % AHI Improvement ProSomnus has +1,800bps Better Mean AHI Improvement 70% 65% 60% 55% 50% 45% 1. 0 Competitor #1 Style Legacy Medicare Devices 100 200 Competitor #3 Style Competitor #2 Style 300 400 Total Sample Size Comfortable and easy-to-use Clinically superior due to precision, titration and customizability 500 ProSomnus 600 700 ProSomnus EVO is the #1 U.S. Prescribed OAT PROSOMNUS SLEEP TECHNOLOGIES Competitor #2 2 3 2020A 2021A Growth ProSomnus Addresses Key Issues With Legacy OATS Minimal side effects, staining or bio-gunk More economical and durable, with single low cost payment every 3 to 5 years PROSOMNUS SLEEP TECHNOLOGIES 19% 67% 2017A-2021A CAGR ~40% 1% Significantly faster patient journey time and product manufacturing turnaround Digital Al-driven manufacturing Ramar K, Dort LC, Katz SG, Lettieri CJ, Harrod CG, Thomas SM, Chervin RD. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. Journal of Dental Sleep Medicine 2015;2(3):71- 125. ProSomnus meta-analysis based upon 7 studies published in peer reviewed medical journals, last updated July 2021. Represents ProSomnus North America prescriber sales growth 2. 3. Represents Competitor #2 North America segment revenue growth; graph represents revenue growth on a calendar year basis 30 STRICTLY CONFIDENTIAL

View entire presentation